Guggenheim Issues Pessimistic Forecast for DBV Technologies (NASDAQ:DBVT) Stock Price

Key Points

• Guggenheim lowered its DBV Technologies price target from $51 to $46 while maintaining a “buy” rating, implying substantial upside from the stock’s prior close.
• DBVT shares opened at $10.03, down 2.6%, and remain well below their 52-week high of $26.18. The company reported a quarterly EPS loss of $0.70, missing the $0.26 loss estimate.
• Analyst sentiment is mixed but leans positive: five analysts rate the stock a buy versus one sell, producing a “Moderate Buy” consensus and an average price target of $45.25.

DBV Technologies (NASDAQ:DBVT - Get Free Report) had its price objective cut by equities researchers at Guggenheim from $51.00 to $46.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price target points to a potential upside of 358.85% from the stock's previous close.

A number of other equities research analysts have also recently commented on DBVT. Cantor Fitzgerald reiterated an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Wall Street Zen downgraded DBV Technologies from a "hold" rating to a "sell" rating in a research report on Saturday, July 4th. Weiss Ratings restated a "sell (e+)" rating on shares of DBV Technologies in a report on Thursday, October 15th. Citigroup restated a "market outperform" rating on shares of DBV Technologies in a research note on Thursday. Finally, HC Wainwright reissued a "buy" rating on shares of DBV Technologies in a report on Friday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $45.25.

DBV Technologies Stock Down 2.6%

DBV Technologies stock opened at $10.03 on Friday. The company's 50 day moving average price is $11.62 and its two-hundred day moving average price is $16.97. DBV Technologies has a 52 week low of $8.63 and a 52 week high of $26.18. The stock has a market cap of $630.35 million, a P/E ratio of -3.33 and a beta of -1.04.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.44). The business had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.56 million. DBV Technologies had a negative return on equity of 115.81% and a negative net margin of 5,392.17%. On average, equities analysts anticipate that DBV Technologies will post -2.05 EPS for the current year.

Institutional Trading of DBV Technologies

A number of large investors have recently made changes to their positions in the company. Perceptive Advisors LLC acquired a new stake in shares of DBV Technologies during the first quarter worth about $20,146,000. Elmind Capital LP purchased a new stake in DBV Technologies during the 1st quarter valued at approximately $5,536,000. Dorsey Wright & Associates acquired a new stake in DBV Technologies during the 1st quarter worth approximately $2,142,000. Diversify Wealth Management LLC acquired a new stake in DBV Technologies during the 1st quarter worth approximately $1,293,000. Finally, Vivo Capital LLC grew its stake in shares of DBV Technologies by 8.4% in the 1st quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock valued at $55,726,000 after purchasing an additional 205,943 shares during the last quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA NASDAQ: DBVT is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies' lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.